Onconic Therapeutics Expands to Indonesia with Zacubo through Supply Agreement with Dexa Medica

Dexa Medica to Handle Local Approval and Sales,
Onconic to Supply Finished Products
Expanding into the Southeast Asian Market Following China, India, and Mexico

Onconic Therapeutics' gastroesophageal reflux disease (GERD) treatment, Zacubo, is entering the Indonesian market.

Onconic Therapeutics company logo image. Onconic Therapeutics

On June 11, Onconic Therapeutics announced that it had signed a license and supply agreement for Zacubo (ingredient name: Zastaprazan) with the Indonesian pharmaceutical company Dexa Medica.

Under this agreement, Dexa Medica will be responsible for obtaining product approval and handling sales in Indonesia, while Onconic Therapeutics will supply the finished products. Details such as the scale of the contract have not been disclosed.

Dexa Medica is a local pharmaceutical company with a sales and distribution network across Indonesia. Through its subsidiary, Medela Potentia, it operates a pharmaceutical distribution business and has extensive experience in importing and commercializing various overseas medicines.

Indonesia is considered the largest market in Southeast Asia, with a population of approximately 280 million. The market for gastroesophageal reflux disease treatments continues to show annual growth, and demand for related pharmaceuticals is increasing due to improved medical accessibility and the expansion of health insurance coverage.

Onconic Therapeutics has currently applied for product approval for Zacubo in China and is conducting Phase 3 clinical trials to secure additional indications. Recently, the company has also completed approval applications in India and Mexico, further expanding its entry into overseas markets.

This content was produced with the assistance of AI translation services.